Phase I of XKH001Injection in Healthy Adults

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
XKH001is a recombinant humanized monoclonal IgG1 antibody for subcutaneous injection. XKH001 specifically blocks interleukin-25 from binding to its receptors. To evaluate the safety, tolerability, pharmacokinetics (PK) of single ascending doses of XKH001 injection following subcutaneous administration
Epistemonikos ID: b1ae0a3d50846a2ed201098c87fb9aff8e97fcb7
First added on: May 09, 2024